FILE PHOTO: A handout photo shows vials during the production of "Gam-COVID-Vac" vaccine against the coronavirus disease (COVID-19), developed by the Gamaleya National Research Institute of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), at Binnopharm pharmaceutical company in Zelenograd near Moscow, Russia August 7, 2020. Picture taken August 7, 2020. The Russian Direct Investment Fund (RDIF)/Andrey Rudakov/Handout via REUTERS
(Reuters) - Russia's "Sputnik-V" COVID-19 vaccine produced an antibody response in all participants in early-stage trials, according to results published on Friday by The Lancet medical journal that were hailed by Moscow as an answer to its critics.
Following are comments from experts on the results of the trials:
Limited time offer:
Just RM5 per month.
